Paclitaxel Injection

This product is a new anti-microtubule drug that promotes tubulin polymerization and inhibits depolymerization, maintains tubulin stability, and inhibits cell mitosis. In vitro experiments have shown that paclitaxel has a significant radiosensitization effect, which may be to stop cells in the G2 and M phases that are sensitive to radiotherapy.

The chemical name of this product is: 5beta;, 20-epoxy-1, 2alpha;, 4, 7beta;, 10beta;, 13alpha;-hexahydroxytaxane-11-ene-9-one-4, 10-diacetate-2-benzoate-13-[(2R, 3S)-N-benzoyl-3-phenylisoserine ester, molecular formula: C47H51NO14 molecular weight: 853.92

This product is a colorless or light yellow clear viscous liquid.

First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.

To prevent allergic reactions, take dexamethasone 20 mg orally 12 hours and 6 hours before paclitaxel treatment, 50 mg of diphenhydramine 50 mg intramuscularly or orally 30 to 60 minutes before treatment, and 300 mg of cimetidine or 50 mg of ranitidine intravenously. The single-drug dose is 135 to 200 mg/m2, and with the support of granulocyte colony-stimulating factor (G-CSF), the dose can reach 250 mg/m2. Dilute paclitaxel with saline, 5% glucose, or 5% glucose saline to a 0.3 to 1.2 mg/ml solution and drip it intravenously for 3 hours. The combined dose is 135 to 175 mg/m2, repeated every 3 to 4 weeks.

1 Allergic reaction: The incidence is 39%, of which the incidence of severe allergic reaction is 2%. Most of them are type 1 allergic reactions, manifested as bronchospasm, dyspnea, urticaria and hypotension. Almost all reactions occur in the first 10 minutes after medication. 2 Bone marrow suppression: It is the main dose-limiting toxicity, manifested as neutropenia, thrombocytopenia is rare, and generally occurs 8 to 10 days after medication. The incidence of severe neutropenia is 47%, and the incidence of severe thrombocytopenia is 5%. Anemia is more common. 3 Neurotoxicity: The incidence of peripheral neuropathy is 62%, the most common manifestations are mild numbness and paresthesia, and the incidence of severe neurotoxicity is 6%. 4 Cardiovascular toxicity: There may be hypotension and asymptomatic short-term bradycardia. 30% have abnormal electrocardiogram changes. 5 Muscle and joint pain: The incidence is 55%, occurring in the joints of the limbs, and the incidence and severity are dose-dependent. 6 Gastrointestinal reactions: The incidences of nausea, vomiting, diarrhea and mucositis are 59%, 43% and 39% respectively, generally mild and moderate. 7. Hepatotoxicity: ALT, AST and AKP increased. 8. Alopecia: The incidence rate is 80%. 9. Local reaction: Inflammation of the infusion vein and local drug extravasation.

1. Those who are allergic to this product or other drugs prepared with polyoxyethylene castor oil. 2. Those with white blood cell count lower than 1.5 times; 109/L and severe bone marrow suppression. 3. Pregnant and lactating women.

Precautions for children: Precautions for pregnancy and lactation: Paclitaxel has been shown to affect embryonic growth in animal experiments, so it is contraindicated for pregnant women. Women of childbearing age should not become pregnant during treatment. Precautions for the elderly:

1 Since quinupristin/dalfopristin is a cytochrome P450-3A4 enzyme inhibitor, simultaneous administration can increase the blood concentration of this drug. 2 When used in combination with telazoma, the serum trough concentration level of telazoma increases by about 1.5 times. Clinical trials have shown that the combination of the two has a better effect. 3 Cisplatin can reduce the clearance rate of this drug by about 1/3. If this drug is given after cisplatin, it can produce more severe bone marrow suppression. 4 When used in combination with doxorubicin, studies have shown that continuous infusion of this drug for 24 hours and then continuous infusion of doxorubicin for 48 hours can significantly reduce the clearance rate of doxorubicin and aggravate neutropenia and stomatitis. 5 Immediate administration of epirubicin after using this drug can aggravate the toxicity of this drug. 6 Ketoconazole can inhibit the metabolism of this drug. 7 Fosphenytoin and phenytoin can reduce the effect of this drug by inducing cytochrome P450. 8 When using this drug, vaccination with live vaccines (such as rotavirus vaccine) can increase the risk of infection with live vaccines. Foreign data recommend that vaccination with live vaccines is prohibited when using this drug. Leukemia patients in remission should wait at least three months after the end of chemotherapy before receiving live vaccines.

Keep away from light and store in a sealed container below 25℃.

16.7ml:100mg

24 months

Haikou Pharmaceutical Factory Co., Ltd.

• Founded in:

  1990-03-09

• Address:

  No. 192, Nanhai Avenue, Xiuying District, Haikou City, Hainan Province

• Tax NO.:

  91460100984090386D

• Registered Funds:

  562.352031 yuan

• Email:

  Log in to view